[
  {
    "sentence": "Open in a new tabResults\nDescription of studies\nResults of the search\nElectronic searches yielded a total of 1291 records, as of February 27, 2018 (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In summary, we included a total of 38 reports (of 34 studies), excluded 29 reports (of 29 studies), classified 20 reports (of 20 studies) as ongoing, and classified 8 records (of 5 studies) as awaiting classification (Figure 1).Included studies\nWe included 34 trials in this review.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We have listed 12 'ongoing studies' under Characteristics of ongoing studies, although eight of the trials listed on clinical trial registries were listed to have completed participant recruitment, but had not yet published their findings.Risk of bias in included studies\nWe have summarized risk of bias assessment in Figure 2 and Figure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis (Analysis 1.1, Figure 4), based upon the availability of quantitative data, was performed by combining data from four studies, reported as mean change from baseline (Asbell 2018; Deinema 2017; Goyal 2017) or mean score at study endpoint (Kangari 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We extracted relevant quantitative data from six studies (Asbell 2018; Bhargava 2015a; Bhargava 2016a; Bhargava 2016b; Deinema 2017; Kangari 2013) (Analysis 1.3, Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As summarized in Figure 6 (Analysis 1.4), two studies reported quantitative TBUT data as mean change from baseline at the study endpoint (Asbell 2018; Deinema 2017), and three trials reported data as mean values at the end of the study follow‐up period (Bhargava 2015a; Bhargava 2016a; Bhargava 2016b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nComparison 1 Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) versus placebo, Outcome 4 Tear break‐up time (TBUT) measured using fluorescein (seconds).The overall summary estimate for these studies suggested an improvement in TBUT with long‐chain omega‐3 PUFA supplementation relative to the control (five studies, MD 2.53, 95% CI 1.17 to 3.94 seconds); however pooled data for this result are not shown in Figure 6 (Analysis 1.4) due to high levels of heterogeneity (I² = 98%).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Three of these studies provided sufficient data for a meta‐analysis related to gastrointestinal adverse effects (Analysis 1.6; Figure 7) (Asbell 2018; Bhargava 2016a; Deinema 2017).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies (Figure 8, Analysis 2.1) showed no difference between the PUFA and placebo supplement groups (four studies, 455 participants; MD 0.66, 95% CI ‐0.45 to 1.77 mm/5 min).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies, for which TBUT was reported as change from baseline (Brignole‐Baudouin 2011; Creuzot 2006), or as change at the study endpoint (Creuzot‐Garcher 2011; Oral sea buckthorn oil study 2010), revealed significant improvement (increase) with combined omega‐3 and omega‐6 supplementation relative to placebo (four studies, 455 participants; MD 0.55, 95% CI 0.04 to 1.07 seconds) (Analysis 2.2; Figure 9).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In addition, the study authors reported that the \"OSDI improvement was significantly higher in the (omega‐3) treatment group in comparison to the control group (p=0.026).\"\nCombining data from these two studies (Analysis 3.1; Figure 10), which had negligible heterogeneity (I² = 0%) revealed a significantly improved (lower) OSDI score at the study endpoint with omega‐3 supplementation with conventional therapy relative to conventional therapy alone (two studies, 70 participants; MD ‐7.16, 95% CI ‐13.97 to ‐0.34).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis, based upon the availability of quantitative data, was performed by combining data from two studies, reported as mean change from baseline (Epitropoulos 2016; NCT01107964) (Analysis 4.1, Figure 11).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Two of these studies provided sufficient data for a meta‐analysis (Analysis 4.5, Figure 12) related to gastrointestinal adverse effects (NCT01107964; Oleñik 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Open in a new tabResults\nDescription of studies\nResults of the search\nElectronic searches yielded a total of 1291 records, as of February 27, 2018 (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In summary, we included a total of 38 reports (of 34 studies), excluded 29 reports (of 29 studies), classified 20 reports (of 20 studies) as ongoing, and classified 8 records (of 5 studies) as awaiting classification (Figure 1).Included studies\nWe included 34 trials in this review.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We have listed 12 'ongoing studies' under Characteristics of ongoing studies, although eight of the trials listed on clinical trial registries were listed to have completed participant recruitment, but had not yet published their findings.Risk of bias in included studies\nWe have summarized risk of bias assessment in Figure 2 and Figure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis (Analysis 1.1, Figure 4), based upon the availability of quantitative data, was performed by combining data from four studies, reported as mean change from baseline (Asbell 2018; Deinema 2017; Goyal 2017) or mean score at study endpoint (Kangari 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We extracted relevant quantitative data from six studies (Asbell 2018; Bhargava 2015a; Bhargava 2016a; Bhargava 2016b; Deinema 2017; Kangari 2013) (Analysis 1.3, Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As summarized in Figure 6 (Analysis 1.4), two studies reported quantitative TBUT data as mean change from baseline at the study endpoint (Asbell 2018; Deinema 2017), and three trials reported data as mean values at the end of the study follow‐up period (Bhargava 2015a; Bhargava 2016a; Bhargava 2016b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nComparison 1 Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) versus placebo, Outcome 4 Tear break‐up time (TBUT) measured using fluorescein (seconds).The overall summary estimate for these studies suggested an improvement in TBUT with long‐chain omega‐3 PUFA supplementation relative to the control (five studies, MD 2.53, 95% CI 1.17 to 3.94 seconds); however pooled data for this result are not shown in Figure 6 (Analysis 1.4) due to high levels of heterogeneity (I² = 98%).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Three of these studies provided sufficient data for a meta‐analysis related to gastrointestinal adverse effects (Analysis 1.6; Figure 7) (Asbell 2018; Bhargava 2016a; Deinema 2017).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies (Figure 8, Analysis 2.1) showed no difference between the PUFA and placebo supplement groups (four studies, 455 participants; MD 0.66, 95% CI ‐0.45 to 1.77 mm/5 min).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies, for which TBUT was reported as change from baseline (Brignole‐Baudouin 2011; Creuzot 2006), or as change at the study endpoint (Creuzot‐Garcher 2011; Oral sea buckthorn oil study 2010), revealed significant improvement (increase) with combined omega‐3 and omega‐6 supplementation relative to placebo (four studies, 455 participants; MD 0.55, 95% CI 0.04 to 1.07 seconds) (Analysis 2.2; Figure 9).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In addition, the study authors reported that the \"OSDI improvement was significantly higher in the (omega‐3) treatment group in comparison to the control group (p=0.026).\"\nCombining data from these two studies (Analysis 3.1; Figure 10), which had negligible heterogeneity (I² = 0%) revealed a significantly improved (lower) OSDI score at the study endpoint with omega‐3 supplementation with conventional therapy relative to conventional therapy alone (two studies, 70 participants; MD ‐7.16, 95% CI ‐13.97 to ‐0.34).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis, based upon the availability of quantitative data, was performed by combining data from two studies, reported as mean change from baseline (Epitropoulos 2016; NCT01107964) (Analysis 4.1, Figure 11).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Two of these studies provided sufficient data for a meta‐analysis (Analysis 4.5, Figure 12) related to gastrointestinal adverse effects (NCT01107964; Oleñik 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Open in a new tabResults\nDescription of studies\nResults of the search\nElectronic searches yielded a total of 1291 records, as of February 27, 2018 (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In summary, we included a total of 38 reports (of 34 studies), excluded 29 reports (of 29 studies), classified 20 reports (of 20 studies) as ongoing, and classified 8 records (of 5 studies) as awaiting classification (Figure 1).Included studies\nWe included 34 trials in this review.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We have listed 12 'ongoing studies' under Characteristics of ongoing studies, although eight of the trials listed on clinical trial registries were listed to have completed participant recruitment, but had not yet published their findings.Risk of bias in included studies\nWe have summarized risk of bias assessment in Figure 2 and Figure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis (Analysis 1.1, Figure 4), based upon the availability of quantitative data, was performed by combining data from four studies, reported as mean change from baseline (Asbell 2018; Deinema 2017; Goyal 2017) or mean score at study endpoint (Kangari 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We extracted relevant quantitative data from six studies (Asbell 2018; Bhargava 2015a; Bhargava 2016a; Bhargava 2016b; Deinema 2017; Kangari 2013) (Analysis 1.3, Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As summarized in Figure 6 (Analysis 1.4), two studies reported quantitative TBUT data as mean change from baseline at the study endpoint (Asbell 2018; Deinema 2017), and three trials reported data as mean values at the end of the study follow‐up period (Bhargava 2015a; Bhargava 2016a; Bhargava 2016b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nComparison 1 Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) versus placebo, Outcome 4 Tear break‐up time (TBUT) measured using fluorescein (seconds).The overall summary estimate for these studies suggested an improvement in TBUT with long‐chain omega‐3 PUFA supplementation relative to the control (five studies, MD 2.53, 95% CI 1.17 to 3.94 seconds); however pooled data for this result are not shown in Figure 6 (Analysis 1.4) due to high levels of heterogeneity (I² = 98%).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Three of these studies provided sufficient data for a meta‐analysis related to gastrointestinal adverse effects (Analysis 1.6; Figure 7) (Asbell 2018; Bhargava 2016a; Deinema 2017).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies (Figure 8, Analysis 2.1) showed no difference between the PUFA and placebo supplement groups (four studies, 455 participants; MD 0.66, 95% CI ‐0.45 to 1.77 mm/5 min).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies, for which TBUT was reported as change from baseline (Brignole‐Baudouin 2011; Creuzot 2006), or as change at the study endpoint (Creuzot‐Garcher 2011; Oral sea buckthorn oil study 2010), revealed significant improvement (increase) with combined omega‐3 and omega‐6 supplementation relative to placebo (four studies, 455 participants; MD 0.55, 95% CI 0.04 to 1.07 seconds) (Analysis 2.2; Figure 9).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In addition, the study authors reported that the \"OSDI improvement was significantly higher in the (omega‐3) treatment group in comparison to the control group (p=0.026).\"\nCombining data from these two studies (Analysis 3.1; Figure 10), which had negligible heterogeneity (I² = 0%) revealed a significantly improved (lower) OSDI score at the study endpoint with omega‐3 supplementation with conventional therapy relative to conventional therapy alone (two studies, 70 participants; MD ‐7.16, 95% CI ‐13.97 to ‐0.34).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis, based upon the availability of quantitative data, was performed by combining data from two studies, reported as mean change from baseline (Epitropoulos 2016; NCT01107964) (Analysis 4.1, Figure 11).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Two of these studies provided sufficient data for a meta‐analysis (Analysis 4.5, Figure 12) related to gastrointestinal adverse effects (NCT01107964; Oleñik 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Open in a new tabResults\nDescription of studies\nResults of the search\nElectronic searches yielded a total of 1291 records, as of February 27, 2018 (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In summary, we included a total of 38 reports (of 34 studies), excluded 29 reports (of 29 studies), classified 20 reports (of 20 studies) as ongoing, and classified 8 records (of 5 studies) as awaiting classification (Figure 1).Included studies\nWe included 34 trials in this review.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We have listed 12 'ongoing studies' under Characteristics of ongoing studies, although eight of the trials listed on clinical trial registries were listed to have completed participant recruitment, but had not yet published their findings.Risk of bias in included studies\nWe have summarized risk of bias assessment in Figure 2 and Figure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis (Analysis 1.1, Figure 4), based upon the availability of quantitative data, was performed by combining data from four studies, reported as mean change from baseline (Asbell 2018; Deinema 2017; Goyal 2017) or mean score at study endpoint (Kangari 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We extracted relevant quantitative data from six studies (Asbell 2018; Bhargava 2015a; Bhargava 2016a; Bhargava 2016b; Deinema 2017; Kangari 2013) (Analysis 1.3, Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As summarized in Figure 6 (Analysis 1.4), two studies reported quantitative TBUT data as mean change from baseline at the study endpoint (Asbell 2018; Deinema 2017), and three trials reported data as mean values at the end of the study follow‐up period (Bhargava 2015a; Bhargava 2016a; Bhargava 2016b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nComparison 1 Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) versus placebo, Outcome 4 Tear break‐up time (TBUT) measured using fluorescein (seconds).The overall summary estimate for these studies suggested an improvement in TBUT with long‐chain omega‐3 PUFA supplementation relative to the control (five studies, MD 2.53, 95% CI 1.17 to 3.94 seconds); however pooled data for this result are not shown in Figure 6 (Analysis 1.4) due to high levels of heterogeneity (I² = 98%).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Three of these studies provided sufficient data for a meta‐analysis related to gastrointestinal adverse effects (Analysis 1.6; Figure 7) (Asbell 2018; Bhargava 2016a; Deinema 2017).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies (Figure 8, Analysis 2.1) showed no difference between the PUFA and placebo supplement groups (four studies, 455 participants; MD 0.66, 95% CI ‐0.45 to 1.77 mm/5 min).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies, for which TBUT was reported as change from baseline (Brignole‐Baudouin 2011; Creuzot 2006), or as change at the study endpoint (Creuzot‐Garcher 2011; Oral sea buckthorn oil study 2010), revealed significant improvement (increase) with combined omega‐3 and omega‐6 supplementation relative to placebo (four studies, 455 participants; MD 0.55, 95% CI 0.04 to 1.07 seconds) (Analysis 2.2; Figure 9).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In addition, the study authors reported that the \"OSDI improvement was significantly higher in the (omega‐3) treatment group in comparison to the control group (p=0.026).\"\nCombining data from these two studies (Analysis 3.1; Figure 10), which had negligible heterogeneity (I² = 0%) revealed a significantly improved (lower) OSDI score at the study endpoint with omega‐3 supplementation with conventional therapy relative to conventional therapy alone (two studies, 70 participants; MD ‐7.16, 95% CI ‐13.97 to ‐0.34).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis, based upon the availability of quantitative data, was performed by combining data from two studies, reported as mean change from baseline (Epitropoulos 2016; NCT01107964) (Analysis 4.1, Figure 11).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Two of these studies provided sufficient data for a meta‐analysis (Analysis 4.5, Figure 12) related to gastrointestinal adverse effects (NCT01107964; Oleñik 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Open in a new tabResults\nDescription of studies\nResults of the search\nElectronic searches yielded a total of 1291 records, as of February 27, 2018 (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In summary, we included a total of 38 reports (of 34 studies), excluded 29 reports (of 29 studies), classified 20 reports (of 20 studies) as ongoing, and classified 8 records (of 5 studies) as awaiting classification (Figure 1).Included studies\nWe included 34 trials in this review.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We have listed 12 'ongoing studies' under Characteristics of ongoing studies, although eight of the trials listed on clinical trial registries were listed to have completed participant recruitment, but had not yet published their findings.Risk of bias in included studies\nWe have summarized risk of bias assessment in Figure 2 and Figure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis (Analysis 1.1, Figure 4), based upon the availability of quantitative data, was performed by combining data from four studies, reported as mean change from baseline (Asbell 2018; Deinema 2017; Goyal 2017) or mean score at study endpoint (Kangari 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We extracted relevant quantitative data from six studies (Asbell 2018; Bhargava 2015a; Bhargava 2016a; Bhargava 2016b; Deinema 2017; Kangari 2013) (Analysis 1.3, Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As summarized in Figure 6 (Analysis 1.4), two studies reported quantitative TBUT data as mean change from baseline at the study endpoint (Asbell 2018; Deinema 2017), and three trials reported data as mean values at the end of the study follow‐up period (Bhargava 2015a; Bhargava 2016a; Bhargava 2016b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nComparison 1 Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) versus placebo, Outcome 4 Tear break‐up time (TBUT) measured using fluorescein (seconds).The overall summary estimate for these studies suggested an improvement in TBUT with long‐chain omega‐3 PUFA supplementation relative to the control (five studies, MD 2.53, 95% CI 1.17 to 3.94 seconds); however pooled data for this result are not shown in Figure 6 (Analysis 1.4) due to high levels of heterogeneity (I² = 98%).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Three of these studies provided sufficient data for a meta‐analysis related to gastrointestinal adverse effects (Analysis 1.6; Figure 7) (Asbell 2018; Bhargava 2016a; Deinema 2017).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies (Figure 8, Analysis 2.1) showed no difference between the PUFA and placebo supplement groups (four studies, 455 participants; MD 0.66, 95% CI ‐0.45 to 1.77 mm/5 min).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies, for which TBUT was reported as change from baseline (Brignole‐Baudouin 2011; Creuzot 2006), or as change at the study endpoint (Creuzot‐Garcher 2011; Oral sea buckthorn oil study 2010), revealed significant improvement (increase) with combined omega‐3 and omega‐6 supplementation relative to placebo (four studies, 455 participants; MD 0.55, 95% CI 0.04 to 1.07 seconds) (Analysis 2.2; Figure 9).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In addition, the study authors reported that the \"OSDI improvement was significantly higher in the (omega‐3) treatment group in comparison to the control group (p=0.026).\"\nCombining data from these two studies (Analysis 3.1; Figure 10), which had negligible heterogeneity (I² = 0%) revealed a significantly improved (lower) OSDI score at the study endpoint with omega‐3 supplementation with conventional therapy relative to conventional therapy alone (two studies, 70 participants; MD ‐7.16, 95% CI ‐13.97 to ‐0.34).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis, based upon the availability of quantitative data, was performed by combining data from two studies, reported as mean change from baseline (Epitropoulos 2016; NCT01107964) (Analysis 4.1, Figure 11).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Two of these studies provided sufficient data for a meta‐analysis (Analysis 4.5, Figure 12) related to gastrointestinal adverse effects (NCT01107964; Oleñik 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Open in a new tabResults\nDescription of studies\nResults of the search\nElectronic searches yielded a total of 1291 records, as of February 27, 2018 (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In summary, we included a total of 38 reports (of 34 studies), excluded 29 reports (of 29 studies), classified 20 reports (of 20 studies) as ongoing, and classified 8 records (of 5 studies) as awaiting classification (Figure 1).Included studies\nWe included 34 trials in this review.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We have listed 12 'ongoing studies' under Characteristics of ongoing studies, although eight of the trials listed on clinical trial registries were listed to have completed participant recruitment, but had not yet published their findings.Risk of bias in included studies\nWe have summarized risk of bias assessment in Figure 2 and Figure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis (Analysis 1.1, Figure 4), based upon the availability of quantitative data, was performed by combining data from four studies, reported as mean change from baseline (Asbell 2018; Deinema 2017; Goyal 2017) or mean score at study endpoint (Kangari 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We extracted relevant quantitative data from six studies (Asbell 2018; Bhargava 2015a; Bhargava 2016a; Bhargava 2016b; Deinema 2017; Kangari 2013) (Analysis 1.3, Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As summarized in Figure 6 (Analysis 1.4), two studies reported quantitative TBUT data as mean change from baseline at the study endpoint (Asbell 2018; Deinema 2017), and three trials reported data as mean values at the end of the study follow‐up period (Bhargava 2015a; Bhargava 2016a; Bhargava 2016b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nComparison 1 Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) versus placebo, Outcome 4 Tear break‐up time (TBUT) measured using fluorescein (seconds).The overall summary estimate for these studies suggested an improvement in TBUT with long‐chain omega‐3 PUFA supplementation relative to the control (five studies, MD 2.53, 95% CI 1.17 to 3.94 seconds); however pooled data for this result are not shown in Figure 6 (Analysis 1.4) due to high levels of heterogeneity (I² = 98%).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Three of these studies provided sufficient data for a meta‐analysis related to gastrointestinal adverse effects (Analysis 1.6; Figure 7) (Asbell 2018; Bhargava 2016a; Deinema 2017).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies (Figure 8, Analysis 2.1) showed no difference between the PUFA and placebo supplement groups (four studies, 455 participants; MD 0.66, 95% CI ‐0.45 to 1.77 mm/5 min).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies, for which TBUT was reported as change from baseline (Brignole‐Baudouin 2011; Creuzot 2006), or as change at the study endpoint (Creuzot‐Garcher 2011; Oral sea buckthorn oil study 2010), revealed significant improvement (increase) with combined omega‐3 and omega‐6 supplementation relative to placebo (four studies, 455 participants; MD 0.55, 95% CI 0.04 to 1.07 seconds) (Analysis 2.2; Figure 9).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In addition, the study authors reported that the \"OSDI improvement was significantly higher in the (omega‐3) treatment group in comparison to the control group (p=0.026).\"\nCombining data from these two studies (Analysis 3.1; Figure 10), which had negligible heterogeneity (I² = 0%) revealed a significantly improved (lower) OSDI score at the study endpoint with omega‐3 supplementation with conventional therapy relative to conventional therapy alone (two studies, 70 participants; MD ‐7.16, 95% CI ‐13.97 to ‐0.34).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis, based upon the availability of quantitative data, was performed by combining data from two studies, reported as mean change from baseline (Epitropoulos 2016; NCT01107964) (Analysis 4.1, Figure 11).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Two of these studies provided sufficient data for a meta‐analysis (Analysis 4.5, Figure 12) related to gastrointestinal adverse effects (NCT01107964; Oleñik 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Open in a new tabResults\nDescription of studies\nResults of the search\nElectronic searches yielded a total of 1291 records, as of February 27, 2018 (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In summary, we included a total of 38 reports (of 34 studies), excluded 29 reports (of 29 studies), classified 20 reports (of 20 studies) as ongoing, and classified 8 records (of 5 studies) as awaiting classification (Figure 1).Included studies\nWe included 34 trials in this review.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We have listed 12 'ongoing studies' under Characteristics of ongoing studies, although eight of the trials listed on clinical trial registries were listed to have completed participant recruitment, but had not yet published their findings.Risk of bias in included studies\nWe have summarized risk of bias assessment in Figure 2 and Figure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis (Analysis 1.1, Figure 4), based upon the availability of quantitative data, was performed by combining data from four studies, reported as mean change from baseline (Asbell 2018; Deinema 2017; Goyal 2017) or mean score at study endpoint (Kangari 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We extracted relevant quantitative data from six studies (Asbell 2018; Bhargava 2015a; Bhargava 2016a; Bhargava 2016b; Deinema 2017; Kangari 2013) (Analysis 1.3, Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As summarized in Figure 6 (Analysis 1.4), two studies reported quantitative TBUT data as mean change from baseline at the study endpoint (Asbell 2018; Deinema 2017), and three trials reported data as mean values at the end of the study follow‐up period (Bhargava 2015a; Bhargava 2016a; Bhargava 2016b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nComparison 1 Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) versus placebo, Outcome 4 Tear break‐up time (TBUT) measured using fluorescein (seconds).The overall summary estimate for these studies suggested an improvement in TBUT with long‐chain omega‐3 PUFA supplementation relative to the control (five studies, MD 2.53, 95% CI 1.17 to 3.94 seconds); however pooled data for this result are not shown in Figure 6 (Analysis 1.4) due to high levels of heterogeneity (I² = 98%).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Three of these studies provided sufficient data for a meta‐analysis related to gastrointestinal adverse effects (Analysis 1.6; Figure 7) (Asbell 2018; Bhargava 2016a; Deinema 2017).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies (Figure 8, Analysis 2.1) showed no difference between the PUFA and placebo supplement groups (four studies, 455 participants; MD 0.66, 95% CI ‐0.45 to 1.77 mm/5 min).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies, for which TBUT was reported as change from baseline (Brignole‐Baudouin 2011; Creuzot 2006), or as change at the study endpoint (Creuzot‐Garcher 2011; Oral sea buckthorn oil study 2010), revealed significant improvement (increase) with combined omega‐3 and omega‐6 supplementation relative to placebo (four studies, 455 participants; MD 0.55, 95% CI 0.04 to 1.07 seconds) (Analysis 2.2; Figure 9).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In addition, the study authors reported that the \"OSDI improvement was significantly higher in the (omega‐3) treatment group in comparison to the control group (p=0.026).\"\nCombining data from these two studies (Analysis 3.1; Figure 10), which had negligible heterogeneity (I² = 0%) revealed a significantly improved (lower) OSDI score at the study endpoint with omega‐3 supplementation with conventional therapy relative to conventional therapy alone (two studies, 70 participants; MD ‐7.16, 95% CI ‐13.97 to ‐0.34).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis, based upon the availability of quantitative data, was performed by combining data from two studies, reported as mean change from baseline (Epitropoulos 2016; NCT01107964) (Analysis 4.1, Figure 11).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Two of these studies provided sufficient data for a meta‐analysis (Analysis 4.5, Figure 12) related to gastrointestinal adverse effects (NCT01107964; Oleñik 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Open in a new tabResults\nDescription of studies\nResults of the search\nElectronic searches yielded a total of 1291 records, as of February 27, 2018 (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In summary, we included a total of 38 reports (of 34 studies), excluded 29 reports (of 29 studies), classified 20 reports (of 20 studies) as ongoing, and classified 8 records (of 5 studies) as awaiting classification (Figure 1).Included studies\nWe included 34 trials in this review.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We have listed 12 'ongoing studies' under Characteristics of ongoing studies, although eight of the trials listed on clinical trial registries were listed to have completed participant recruitment, but had not yet published their findings.Risk of bias in included studies\nWe have summarized risk of bias assessment in Figure 2 and Figure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis (Analysis 1.1, Figure 4), based upon the availability of quantitative data, was performed by combining data from four studies, reported as mean change from baseline (Asbell 2018; Deinema 2017; Goyal 2017) or mean score at study endpoint (Kangari 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We extracted relevant quantitative data from six studies (Asbell 2018; Bhargava 2015a; Bhargava 2016a; Bhargava 2016b; Deinema 2017; Kangari 2013) (Analysis 1.3, Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As summarized in Figure 6 (Analysis 1.4), two studies reported quantitative TBUT data as mean change from baseline at the study endpoint (Asbell 2018; Deinema 2017), and three trials reported data as mean values at the end of the study follow‐up period (Bhargava 2015a; Bhargava 2016a; Bhargava 2016b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nComparison 1 Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) versus placebo, Outcome 4 Tear break‐up time (TBUT) measured using fluorescein (seconds).The overall summary estimate for these studies suggested an improvement in TBUT with long‐chain omega‐3 PUFA supplementation relative to the control (five studies, MD 2.53, 95% CI 1.17 to 3.94 seconds); however pooled data for this result are not shown in Figure 6 (Analysis 1.4) due to high levels of heterogeneity (I² = 98%).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Three of these studies provided sufficient data for a meta‐analysis related to gastrointestinal adverse effects (Analysis 1.6; Figure 7) (Asbell 2018; Bhargava 2016a; Deinema 2017).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies (Figure 8, Analysis 2.1) showed no difference between the PUFA and placebo supplement groups (four studies, 455 participants; MD 0.66, 95% CI ‐0.45 to 1.77 mm/5 min).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies, for which TBUT was reported as change from baseline (Brignole‐Baudouin 2011; Creuzot 2006), or as change at the study endpoint (Creuzot‐Garcher 2011; Oral sea buckthorn oil study 2010), revealed significant improvement (increase) with combined omega‐3 and omega‐6 supplementation relative to placebo (four studies, 455 participants; MD 0.55, 95% CI 0.04 to 1.07 seconds) (Analysis 2.2; Figure 9).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In addition, the study authors reported that the \"OSDI improvement was significantly higher in the (omega‐3) treatment group in comparison to the control group (p=0.026).\"\nCombining data from these two studies (Analysis 3.1; Figure 10), which had negligible heterogeneity (I² = 0%) revealed a significantly improved (lower) OSDI score at the study endpoint with omega‐3 supplementation with conventional therapy relative to conventional therapy alone (two studies, 70 participants; MD ‐7.16, 95% CI ‐13.97 to ‐0.34).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis, based upon the availability of quantitative data, was performed by combining data from two studies, reported as mean change from baseline (Epitropoulos 2016; NCT01107964) (Analysis 4.1, Figure 11).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Two of these studies provided sufficient data for a meta‐analysis (Analysis 4.5, Figure 12) related to gastrointestinal adverse effects (NCT01107964; Oleñik 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Results\nDescription of studies\nResults of the search\nElectronic searches yielded a total of 1291 records, as of February 27, 2018 (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In summary, we included a total of 38 reports (of 34 studies), excluded 29 reports (of 29 studies), classified 20 reports (of 20 studies) as ongoing, and classified 8 records (of 5 studies) as awaiting classification (Figure 1).Included studies\nWe included 34 trials in this review.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We have listed 12 'ongoing studies' under Characteristics of ongoing studies, although eight of the trials listed on clinical trial registries were listed to have completed participant recruitment, but had not yet published their findings.Risk of bias in included studies\nWe have summarized risk of bias assessment in Figure 2 and Figure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis (Analysis 1.1, Figure 4), based upon the availability of quantitative data, was performed by combining data from four studies, reported as mean change from baseline (Asbell 2018; Deinema 2017; Goyal 2017) or mean score at study endpoint (Kangari 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We extracted relevant quantitative data from six studies (Asbell 2018; Bhargava 2015a; Bhargava 2016a; Bhargava 2016b; Deinema 2017; Kangari 2013) (Analysis 1.3, Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As summarized in Figure 6 (Analysis 1.4), two studies reported quantitative TBUT data as mean change from baseline at the study endpoint (Asbell 2018; Deinema 2017), and three trials reported data as mean values at the end of the study follow‐up period (Bhargava 2015a; Bhargava 2016a; Bhargava 2016b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nComparison 1 Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) versus placebo, Outcome 4 Tear break‐up time (TBUT) measured using fluorescein (seconds).The overall summary estimate for these studies suggested an improvement in TBUT with long‐chain omega‐3 PUFA supplementation relative to the control (five studies, MD 2.53, 95% CI 1.17 to 3.94 seconds); however pooled data for this result are not shown in Figure 6 (Analysis 1.4) due to high levels of heterogeneity (I² = 98%).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Three of these studies provided sufficient data for a meta‐analysis related to gastrointestinal adverse effects (Analysis 1.6; Figure 7) (Asbell 2018; Bhargava 2016a; Deinema 2017).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies (Figure 8, Analysis 2.1) showed no difference between the PUFA and placebo supplement groups (four studies, 455 participants; MD 0.66, 95% CI ‐0.45 to 1.77 mm/5 min).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies, for which TBUT was reported as change from baseline (Brignole‐Baudouin 2011; Creuzot 2006), or as change at the study endpoint (Creuzot‐Garcher 2011; Oral sea buckthorn oil study 2010), revealed significant improvement (increase) with combined omega‐3 and omega‐6 supplementation relative to placebo (four studies, 455 participants; MD 0.55, 95% CI 0.04 to 1.07 seconds) (Analysis 2.2; Figure 9).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In addition, the study authors reported that the \"OSDI improvement was significantly higher in the (omega‐3) treatment group in comparison to the control group (p=0.026).\"\nCombining data from these two studies (Analysis 3.1; Figure 10), which had negligible heterogeneity (I² = 0%) revealed a significantly improved (lower) OSDI score at the study endpoint with omega‐3 supplementation with conventional therapy relative to conventional therapy alone (two studies, 70 participants; MD ‐7.16, 95% CI ‐13.97 to ‐0.34).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis, based upon the availability of quantitative data, was performed by combining data from two studies, reported as mean change from baseline (Epitropoulos 2016; NCT01107964) (Analysis 4.1, Figure 11).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Two of these studies provided sufficient data for a meta‐analysis (Analysis 4.5, Figure 12) related to gastrointestinal adverse effects (NCT01107964; Oleñik 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Description of studies\nResults of the search\nElectronic searches yielded a total of 1291 records, as of February 27, 2018 (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In summary, we included a total of 38 reports (of 34 studies), excluded 29 reports (of 29 studies), classified 20 reports (of 20 studies) as ongoing, and classified 8 records (of 5 studies) as awaiting classification (Figure 1).Included studies\nWe included 34 trials in this review.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Results of the search\nElectronic searches yielded a total of 1291 records, as of February 27, 2018 (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In summary, we included a total of 38 reports (of 34 studies), excluded 29 reports (of 29 studies), classified 20 reports (of 20 studies) as ongoing, and classified 8 records (of 5 studies) as awaiting classification (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Electronic searches yielded a total of 1291 records, as of February 27, 2018 (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In summary, we included a total of 38 reports (of 34 studies), excluded 29 reports (of 29 studies), classified 20 reports (of 20 studies) as ongoing, and classified 8 records (of 5 studies) as awaiting classification (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Risk of bias in included studies\nWe have summarized risk of bias assessment in Figure 2 and Figure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "We have summarized risk of bias assessment in Figure 2 and Figure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis (Analysis 1.1, Figure 4), based upon the availability of quantitative data, was performed by combining data from four studies, reported as mean change from baseline (Asbell 2018; Deinema 2017; Goyal 2017) or mean score at study endpoint (Kangari 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We extracted relevant quantitative data from six studies (Asbell 2018; Bhargava 2015a; Bhargava 2016a; Bhargava 2016b; Deinema 2017; Kangari 2013) (Analysis 1.3, Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As summarized in Figure 6 (Analysis 1.4), two studies reported quantitative TBUT data as mean change from baseline at the study endpoint (Asbell 2018; Deinema 2017), and three trials reported data as mean values at the end of the study follow‐up period (Bhargava 2015a; Bhargava 2016a; Bhargava 2016b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nComparison 1 Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) versus placebo, Outcome 4 Tear break‐up time (TBUT) measured using fluorescein (seconds).The overall summary estimate for these studies suggested an improvement in TBUT with long‐chain omega‐3 PUFA supplementation relative to the control (five studies, MD 2.53, 95% CI 1.17 to 3.94 seconds); however pooled data for this result are not shown in Figure 6 (Analysis 1.4) due to high levels of heterogeneity (I² = 98%).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Three of these studies provided sufficient data for a meta‐analysis related to gastrointestinal adverse effects (Analysis 1.6; Figure 7) (Asbell 2018; Bhargava 2016a; Deinema 2017).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies (Figure 8, Analysis 2.1) showed no difference between the PUFA and placebo supplement groups (four studies, 455 participants; MD 0.66, 95% CI ‐0.45 to 1.77 mm/5 min).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies, for which TBUT was reported as change from baseline (Brignole‐Baudouin 2011; Creuzot 2006), or as change at the study endpoint (Creuzot‐Garcher 2011; Oral sea buckthorn oil study 2010), revealed significant improvement (increase) with combined omega‐3 and omega‐6 supplementation relative to placebo (four studies, 455 participants; MD 0.55, 95% CI 0.04 to 1.07 seconds) (Analysis 2.2; Figure 9).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In addition, the study authors reported that the \"OSDI improvement was significantly higher in the (omega‐3) treatment group in comparison to the control group (p=0.026).\"\nCombining data from these two studies (Analysis 3.1; Figure 10), which had negligible heterogeneity (I² = 0%) revealed a significantly improved (lower) OSDI score at the study endpoint with omega‐3 supplementation with conventional therapy relative to conventional therapy alone (two studies, 70 participants; MD ‐7.16, 95% CI ‐13.97 to ‐0.34).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis, based upon the availability of quantitative data, was performed by combining data from two studies, reported as mean change from baseline (Epitropoulos 2016; NCT01107964) (Analysis 4.1, Figure 11).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Two of these studies provided sufficient data for a meta‐analysis (Analysis 4.5, Figure 12) related to gastrointestinal adverse effects (NCT01107964; Oleñik 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis (Analysis 1.1, Figure 4), based upon the availability of quantitative data, was performed by combining data from four studies, reported as mean change from baseline (Asbell 2018; Deinema 2017; Goyal 2017) or mean score at study endpoint (Kangari 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We extracted relevant quantitative data from six studies (Asbell 2018; Bhargava 2015a; Bhargava 2016a; Bhargava 2016b; Deinema 2017; Kangari 2013) (Analysis 1.3, Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As summarized in Figure 6 (Analysis 1.4), two studies reported quantitative TBUT data as mean change from baseline at the study endpoint (Asbell 2018; Deinema 2017), and three trials reported data as mean values at the end of the study follow‐up period (Bhargava 2015a; Bhargava 2016a; Bhargava 2016b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nComparison 1 Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) versus placebo, Outcome 4 Tear break‐up time (TBUT) measured using fluorescein (seconds).The overall summary estimate for these studies suggested an improvement in TBUT with long‐chain omega‐3 PUFA supplementation relative to the control (five studies, MD 2.53, 95% CI 1.17 to 3.94 seconds); however pooled data for this result are not shown in Figure 6 (Analysis 1.4) due to high levels of heterogeneity (I² = 98%).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Three of these studies provided sufficient data for a meta‐analysis related to gastrointestinal adverse effects (Analysis 1.6; Figure 7) (Asbell 2018; Bhargava 2016a; Deinema 2017).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis (Analysis 1.1, Figure 4), based upon the availability of quantitative data, was performed by combining data from four studies, reported as mean change from baseline (Asbell 2018; Deinema 2017; Goyal 2017) or mean score at study endpoint (Kangari 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis (Analysis 1.1, Figure 4), based upon the availability of quantitative data, was performed by combining data from four studies, reported as mean change from baseline (Asbell 2018; Deinema 2017; Goyal 2017) or mean score at study endpoint (Kangari 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We extracted relevant quantitative data from six studies (Asbell 2018; Bhargava 2015a; Bhargava 2016a; Bhargava 2016b; Deinema 2017; Kangari 2013) (Analysis 1.3, Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As summarized in Figure 6 (Analysis 1.4), two studies reported quantitative TBUT data as mean change from baseline at the study endpoint (Asbell 2018; Deinema 2017), and three trials reported data as mean values at the end of the study follow‐up period (Bhargava 2015a; Bhargava 2016a; Bhargava 2016b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nComparison 1 Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) versus placebo, Outcome 4 Tear break‐up time (TBUT) measured using fluorescein (seconds).The overall summary estimate for these studies suggested an improvement in TBUT with long‐chain omega‐3 PUFA supplementation relative to the control (five studies, MD 2.53, 95% CI 1.17 to 3.94 seconds); however pooled data for this result are not shown in Figure 6 (Analysis 1.4) due to high levels of heterogeneity (I² = 98%).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "We extracted relevant quantitative data from six studies (Asbell 2018; Bhargava 2015a; Bhargava 2016a; Bhargava 2016b; Deinema 2017; Kangari 2013) (Analysis 1.3, Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "We extracted relevant quantitative data from six studies (Asbell 2018; Bhargava 2015a; Bhargava 2016a; Bhargava 2016b; Deinema 2017; Kangari 2013) (Analysis 1.3, Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As summarized in Figure 6 (Analysis 1.4), two studies reported quantitative TBUT data as mean change from baseline at the study endpoint (Asbell 2018; Deinema 2017), and three trials reported data as mean values at the end of the study follow‐up period (Bhargava 2015a; Bhargava 2016a; Bhargava 2016b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nComparison 1 Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) versus placebo, Outcome 4 Tear break‐up time (TBUT) measured using fluorescein (seconds).The overall summary estimate for these studies suggested an improvement in TBUT with long‐chain omega‐3 PUFA supplementation relative to the control (five studies, MD 2.53, 95% CI 1.17 to 3.94 seconds); however pooled data for this result are not shown in Figure 6 (Analysis 1.4) due to high levels of heterogeneity (I² = 98%).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "As summarized in Figure 6 (Analysis 1.4), two studies reported quantitative TBUT data as mean change from baseline at the study endpoint (Asbell 2018; Deinema 2017), and three trials reported data as mean values at the end of the study follow‐up period (Bhargava 2015a; Bhargava 2016a; Bhargava 2016b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The overall summary estimate for these studies suggested an improvement in TBUT with long‐chain omega‐3 PUFA supplementation relative to the control (five studies, MD 2.53, 95% CI 1.17 to 3.94 seconds); however pooled data for this result are not shown in Figure 6 (Analysis 1.4) due to high levels of heterogeneity (I² = 98%).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Three of these studies provided sufficient data for a meta‐analysis related to gastrointestinal adverse effects (Analysis 1.6; Figure 7) (Asbell 2018; Bhargava 2016a; Deinema 2017).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Three of these studies provided sufficient data for a meta‐analysis related to gastrointestinal adverse effects (Analysis 1.6; Figure 7) (Asbell 2018; Bhargava 2016a; Deinema 2017).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies (Figure 8, Analysis 2.1) showed no difference between the PUFA and placebo supplement groups (four studies, 455 participants; MD 0.66, 95% CI ‐0.45 to 1.77 mm/5 min).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies, for which TBUT was reported as change from baseline (Brignole‐Baudouin 2011; Creuzot 2006), or as change at the study endpoint (Creuzot‐Garcher 2011; Oral sea buckthorn oil study 2010), revealed significant improvement (increase) with combined omega‐3 and omega‐6 supplementation relative to placebo (four studies, 455 participants; MD 0.55, 95% CI 0.04 to 1.07 seconds) (Analysis 2.2; Figure 9).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies (Figure 8, Analysis 2.1) showed no difference between the PUFA and placebo supplement groups (four studies, 455 participants; MD 0.66, 95% CI ‐0.45 to 1.77 mm/5 min).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies, for which TBUT was reported as change from baseline (Brignole‐Baudouin 2011; Creuzot 2006), or as change at the study endpoint (Creuzot‐Garcher 2011; Oral sea buckthorn oil study 2010), revealed significant improvement (increase) with combined omega‐3 and omega‐6 supplementation relative to placebo (four studies, 455 participants; MD 0.55, 95% CI 0.04 to 1.07 seconds) (Analysis 2.2; Figure 9).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies (Figure 8, Analysis 2.1) showed no difference between the PUFA and placebo supplement groups (four studies, 455 participants; MD 0.66, 95% CI ‐0.45 to 1.77 mm/5 min).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies (Figure 8, Analysis 2.1) showed no difference between the PUFA and placebo supplement groups (four studies, 455 participants; MD 0.66, 95% CI ‐0.45 to 1.77 mm/5 min).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies, for which TBUT was reported as change from baseline (Brignole‐Baudouin 2011; Creuzot 2006), or as change at the study endpoint (Creuzot‐Garcher 2011; Oral sea buckthorn oil study 2010), revealed significant improvement (increase) with combined omega‐3 and omega‐6 supplementation relative to placebo (four studies, 455 participants; MD 0.55, 95% CI 0.04 to 1.07 seconds) (Analysis 2.2; Figure 9).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Combining data from these studies, for which TBUT was reported as change from baseline (Brignole‐Baudouin 2011; Creuzot 2006), or as change at the study endpoint (Creuzot‐Garcher 2011; Oral sea buckthorn oil study 2010), revealed significant improvement (increase) with combined omega‐3 and omega‐6 supplementation relative to placebo (four studies, 455 participants; MD 0.55, 95% CI 0.04 to 1.07 seconds) (Analysis 2.2; Figure 9).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In addition, the study authors reported that the \"OSDI improvement was significantly higher in the (omega‐3) treatment group in comparison to the control group (p=0.026).\"\nCombining data from these two studies (Analysis 3.1; Figure 10), which had negligible heterogeneity (I² = 0%) revealed a significantly improved (lower) OSDI score at the study endpoint with omega‐3 supplementation with conventional therapy relative to conventional therapy alone (two studies, 70 participants; MD ‐7.16, 95% CI ‐13.97 to ‐0.34).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "In addition, the study authors reported that the \"OSDI improvement was significantly higher in the (omega‐3) treatment group in comparison to the control group (p=0.026).\"\nCombining data from these two studies (Analysis 3.1; Figure 10), which had negligible heterogeneity (I² = 0%) revealed a significantly improved (lower) OSDI score at the study endpoint with omega‐3 supplementation with conventional therapy relative to conventional therapy alone (two studies, 70 participants; MD ‐7.16, 95% CI ‐13.97 to ‐0.34).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Combining data from these two studies (Analysis 3.1; Figure 10), which had negligible heterogeneity (I² = 0%) revealed a significantly improved (lower) OSDI score at the study endpoint with omega‐3 supplementation with conventional therapy relative to conventional therapy alone (two studies, 70 participants; MD ‐7.16, 95% CI ‐13.97 to ‐0.34).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis, based upon the availability of quantitative data, was performed by combining data from two studies, reported as mean change from baseline (Epitropoulos 2016; NCT01107964) (Analysis 4.1, Figure 11).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Two of these studies provided sufficient data for a meta‐analysis (Analysis 4.5, Figure 12) related to gastrointestinal adverse effects (NCT01107964; Oleñik 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis, based upon the availability of quantitative data, was performed by combining data from two studies, reported as mean change from baseline (Epitropoulos 2016; NCT01107964) (Analysis 4.1, Figure 11).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Meta‐analysis, based upon the availability of quantitative data, was performed by combining data from two studies, reported as mean change from baseline (Epitropoulos 2016; NCT01107964) (Analysis 4.1, Figure 11).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Two of these studies provided sufficient data for a meta‐analysis (Analysis 4.5, Figure 12) related to gastrointestinal adverse effects (NCT01107964; Oleñik 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Two of these studies provided sufficient data for a meta‐analysis (Analysis 4.5, Figure 12) related to gastrointestinal adverse effects (NCT01107964; Oleñik 2013).",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      }
    ]
  }
]